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Abstract 
In this work we designed an antioxidant nanoreactor based on the encapsulation of 
CuZnSOD in amphiphilic copolymer nanovesicles. The nanovesicles are formed by 
self-assembly of amphiphilic copolymer poly-(2-methyloxazoline)-poly-
(dimethylsiloxane)-poly-(2-methyloxazoline) (PMOXA-PDMS-PMOXA). We chose 
this polymer due to its advantages over conventional systems, i.e. liposomes. 
Polymer nanocontainers can be produced with a controlled mean diameter and low 
polydispersity compared to liposomes. They were tested and shown to be more 
stable than liposomes.[1] These represent the main advantages with respect to the 
application as carriers to improve the drug stability and the circulation life-time. 
Another factor which could increase dramatically the circulation life-time and 
therefore the availability of the encapsulated SOD, is the stealth property of the poly-
(2-methyloxazoline) chain, comparable to that of PEG. Besides, the polymer used for 
this study, has an oxygen permeable membrane, as will be shown later. All these 
advantages make the nanoreactors a completely new approach of drug delivery 
systems, in which the cargo is not released, but performs its function within the 
vesicle. 
The nanovesicles, made of poly-(2-methyloxazoline)-poly (dimethylsiloxane)-poly (2-
methyloxazoline), successfully encapsulated the SOD protein during their formation 
by a self-assembling process, as proved by confocal laser-scanning microscopy and 
fluorescence-correlation spectroscopy. Electron paramagnetic resonance 
spectroscopy and circular dichroism analyses showed that no structural changes 
appeared within the proteins once inside the inner cavity of the nanovesicles. The 
function of this antioxidant nanoreactor was tested by pulse radiolysis which 
demonstrated that superoxide dismutase remains active inside the nanovesicles. 
This simple and robust hybrid system provides selective shielding of a sensitive 
enzyme from proteolytic attack and therefore points to a new direction for developing 
drug delivery applications. 
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1 Introduction 
The formulation of pharmaceuticals in drug delivery systems is most challenging, 
since delivery of a broad range of pharmaceuticals with different mode of actions, as 
well as biological and chemical properties, can cause undesired side effects in the 
human body. Furthermore, a multitude of different conditions in the body interfere 
with the delivery of pharmaceuticals to their target, and have a negative impact on 
drug stability. 
Drug delivery systems have to match various requirements with respect to the 
efficiency of a specific drug: (1) to enable the application of pharmaceutically active 
compounds e.g. by increasing their solubility, (2) to protect their cargo from unwanted 
reactions in the human body, e.g. degradation, gastrointestinal irritation, (3) to 
prevent from unwanted side reactions with physiological pathways and organs, and 
(4) to deliver the drug to its site of action. 
To reach all these aims, a variety of strategies has been developed. Nanocontainers, 
often based on lipid- or polymer vesicles or micelles, and drug-polymer conjugates 
are employed to carry pharmaceuticals. The drugs stay protected due to their local 
separation from the environment. Besides, the nanocarrier can be functionalized to 
support specific delivery within the human body. The development of new 
biocompatible materials for drug delivery systems is a crucial factor, since the 
increasing number of new biopharmaceuticals with specific mode of action demand a 
broad portfolio of formulation possibilities. In this study we focus on the application of 
polymer-based vesicles. Polymers offer the unique possibility to be controlled in their 
behavior by their chemistry and architecture, which opens a perspective to create 
nano-sized objects to be applied in bio- and pharmaceutical sciences. 
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1.1 Polymers and block copolymers 
1.1.1 Definitions 
The word 'polymer' derives from Greek, where poly means “many” and meros means 
“part”. They consist of repeating units called monomers, which are covalently 
connected to give high molecular weight compounds. Due to their architecture, they 
can be classified into linear or branched polymers and dendrimers (Figure 1). 
Dendrimers are a special class of branched polymers, which are marked out by 
branched branches. 
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Figure 1 Schematic drawing of different polymer architectures. 
Further classifications can be made, depending on the chemical nature of the 
monomers which form the polymeric chain. Polymers with only one type of 
monomers are called homopolymers (Figure 2). If two different monomers are 
present in one polymer chain, the term copolymer is used. The sequence, in which 
different repeating units appear in copolymers leads to further differentiation. 
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Polymers containing alternating monomers are called alternating copolymers (Figure 
2), while those containing monomers which do not alternate periodically are 
described as random copolymers. If different monomers are grouped together, they 
form blocks, and the polymer built after covalent linking of such blocks is then termed 
a block copolymer (Figure 2). 
Block-copolymers consist of at least two, covalently bound segments or blocks of 
different homopolymers. A diblock-copolymer can have a general form of AnBm, with 
A and B standing for different monomers and n and m giving the degree of 
polymerization (Figure 2). A further differentiation of block-copolymers can be made 
by taking the physico-chemical properties of the blocks into account, such as 
hydrophilicity and hydrophobicity. Polymers, which contain hydrophilic and 
hydrophobic blocks covalently linked together, are named amphiphilic block-
copolymers. 
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Figure 2 Schematic representation of linear polymers. 
1.1.2 Self-assembly of block copolymers 
Self-assembly is defined as the spontaneous building up of complex structures from 
the components of the system, by noncovalent forces. The transition from a 
disordered to an ordered phase can be induced by changing thermodynamic or 
physical parameters, such as temperature, chemical potential (concentration, pH 
value, salt concentration), mechanical fields (pressure, shear, extension, ultrasonic 
field), as well as electric or magnetic fields. The ordered state can be distinguished 
by e.g. the location of molecules at restricted three-dimensional regions. Transferred 
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to the topic of polymer sciences the self-assembly process can be described as 
interplay of different forces, e.g. long-range repulsive forces (e.g. hydrophilic-
hydrophobic), short-range attractive (covalent binding of polymeric blocks) forces, 
chemical or physical incompatibility. One feasibility of self assembly, due to the 
mentioned forces, are short-range attractive and long-range repulsive forces (Figure 
3A). Both blocks, hydrophilic and hydrophobic, of an amphiphilic block copolymer are 
covalently linked together. This linkage represents the short-range attractive forces, 
forcing both blocks to stay together. The long range repulsive forces are caused by 
reciprocal repulsion of the hydrophilic and the hydrophobic block. This contrary 
forces within one molecule, which can’t be avoided, lead to the formation of self 
assembled structures of structures. 
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Figure 3 A) Illustration of long-range repulsive and short-range attractive forces 
leading to B) example of self-organization (with arrows marking short-range attractive 
and long-range repulsive forces). 
Self-assembly of amphiphilic block copolymers in solution can be controlled by taking 
into account several parameters, which induce the directed formation of different 
morphologies, e.g. spheres, rods, lamellae and vesicles. It has been found, that the 
formation of different morphologies (Figure 4) is a function of the total and relative 
block lengths, temperature, chemical nature of each block, type of solvent, and 
concentration.[2, 3] One special feature of block copolymer chemistry is the versatility 
of their chemistry to ensure the right chemical composition, length and structure of 
the constituting blocks in order to tune the association characteristics and thus the 
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obtained morphologies. Moreover, by changing the architecture of the blocks 
different mesophases can be achieved. 
 
Figure 4 Transmission electron micrographs of various types of morphologies formed 
by aggregated block copolymers. a) spherical micelles and b) rod-like micelles from 
polystyrene-b-poly(acrylic acid), c) vesicles from poly(ethylene oxide)-b-
polyethylethylene, d) lamellae from polystyrene-b-poly(phenylquinoline), e) branched 
worm-like micelles from poly(ethylene oxide)-b-polybutadiene, and f) left-hand 
helices from polystyrene-b-poly(L-isocyanoalanyl-L-alanine).[4] 
In the context of drug delivery systems, the most interesting self-assembled 
structures obtained from block copolymers are micelles (Figure 5) and vesicles. Self-
assembly occurs by exceeding a critical aggregation concentration.[5, 6] 
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Figure 5 Scheme of a micelle made from a diblock copolymer 
In aqueous solution, micellization occurs above the critical micelle concentration by 
selective solubilization of the hydrophilic block, while the core is formed by the 
hydrophobic block. Slower dynamics of the constituent blocks [7, 8] makes block 
copolymer micelles more stable compared to lipid micelles. The stability, which is a 
function of the intermicellar chain exchange1 is mainly dependent on the type of 
blocks, e.g. their relative polarity, the overall chain length and the relative block 
length, and can be tailored to be very small in contrast to lipid micelles. Therefore, 
self-assembled structures based on block copolymers show higher structural stability. 
                                            
1 ability of micelles to coalesce and redistribute 
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Depending on the asymmetry of the constituting blocks, micellar structures can be 
classified as star- and crew-cut micelles (Figure 6). The aggregates are called star 
micelles, if the corona-forming block (block exposed to the solvent) is much longer 
than the core-forming block.[9, 10] If the corona-forming block is much shorter than 
the core-forming block, the aggregates are called crew-cut micelles.[11-13] 
 
Figure 6 A) A schematic representation of AB diblock copolymer unimers. B) 
Depending on the ratio of hydrophilic and hydrophobic blocks, the unimers can form 
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star- or crew-cut micelles. C) AB diblock copolymers can also self-assemble into 
vesicular structures. 
Diblock copolymers with long hydrophilic chains tend to form micellar aggregates due 
to the highly positive curvature of the interface. As the length of the insoluble block 
increases, the curvature decreases and a transition to rod-like micelles is observed. If 
the length of the insoluble block increases further, lamellar phases are favored. 
Depending on the water concentration, lamellae can swell to a point, where the 
balance of hydrophilic and hydrophobic forces changes and the membrane rearrange 
to nonpolar configurations. Additional parameters, which control this rearrangements 
is the stiffness and the molecular properties of the membrane. 
Vesicles have been present since the first cell existed, and play a critical role in 
compartmentalization functions, such as transport and biological protection. Due to 
the material vesicles are built from, they are named differently. Vesicles made of 
lipids, which are natural amphiphiles, well known for their ability to self-assemble, are 
named liposomes. Vesicles based on polypeptides, named peptosomes, are reported 
to support the function of biocompatibility.[14-16] Polypeptides are prone to 
hydrolysis, as already widely exploited in the field of controlled drug release. Natural 
and synthetic amphiphilic polymers can generate vesicles in various media, ranging 
from organic solvents to pure aqueous solution. These polymer vesicles are called 
polymersomes, and are of big scientific interest, due to their tunable properties which 
make them very versatile. 
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1.1.3 Polymersomes 
Polymersomes are well-defined nano- or micrometer-sized objects (Figure 7). They 
can be desirable for various applications and therefore material science and 
nanotechnology pay special attention to the development of self-assembling 
materials. Made of amphiphilic block copolymers, the polymersomes represent a 
special class of superstructures. Polymer chemistry offers - by engineering of block 
composition and block length - a great potential to design new materials well suited 
to mimic and replace biological macromolecules. Properties of polymer- and 
liposomes have been compared and it has been found that the polymer membrane 
shows less permeability for water and an increased stability.[6] In this respect, 
polymer vesicles are more versatile since their fluidity properties can be tailored by 
tuning the glass transition temperature of the constituting blocks. The diameter of 
polymersomes can range, as reported, from 100 nm to a few µm.[17] 
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Figure 7 Sheme of a polymersome made from ABA triblock copolymer. The hollow 
sphere morphology can be used for various applications, such as drug delivery or 
reaction vessel. 
Many research groups work on the development of new applications for 
polymersomes. Most of them are used to build compartments, which are a 
requirement in nature for the occurrence of many metabolic processes such as 
oxidation of fatty acids, the citrate cycle, and phosphorylation. Possible applications 
of polymersomes are transport and storage of compounds, chemical reactions of 
various compounds in situ, and targeting after functionalization of the vesicles' 
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surface. In the case of transport and storage, the hollow sphere morphology of the 
polymersomes serves to encapsulate agents, and therefore to protect sensitive 
compounds and to reduce the side effects caused by unspecific reactions. 
Another advantage of polymersomes is the possibility to functionalize covalently their 
surface with different kinds of molecules, e.g. receptor-specific ligands [18] or cell 
penetrating peptides (CPPs).[19] In this way, they are directed to specific sites of 
action and are supported for cellular uptake. It was shown that properties of 
polymersomes can be triggered concerning their permeability, or stimuli-
responsiveness (as for example pH, temperature, or light responsiveness).[20, 21] 
1.1.4 Nanoreactors 
In nature, almost all chemical conversions take place in a confined environment and 
are closely coupled to each other in such a way that the product of one reaction is 
the substrate or catalyst for the subsequent one. Such coupling of reactions in time 
and space is the fundament for highly developed processes in many organism. 
Influencing these processes demands a compartmentalization, too, and is therefore 
of growing interest for scientists. 
Nanoreactors represent one possibility to approach the solution to this problem. 
Nanoreactors could be polymersomes, which are used for advanced applications in 
compartmentalization of chemical reactions. They must fulfill various requirements 
such as (1) efficient entrapment of the catalytic species, (2) stability and robustness 
to ensure protection of catalytic species, (3) selective diffusion of product molecules 
through the membrane, (4) no unwanted reaction to external influences (e.g. pH, 
ionic strength, temperature), and (5) the system must be innocuous to allow its use in 
living systems.[22] 
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Nanoreactors have been used in various applications as nanometer sized reaction 
vessel, e.g. by encapsulation of β-lactamase enzyme inside the water pool together 
with the incorporation of a channel protein into the polymer membrane.[23] 
Furthermore, the ability of nanocontainers was shown to mimic natural cells, as for 
example by the use of a channel protein as a receptor for λ phages. The channel 
protein triggered the ejection of the phage DNA into the inner cavity of the 
vesicle.[24] 
1.1.5 Methods of polymersome preparation 
Various methods of vesicle preparation are described in the literature. The following 
methods are the most conventional and are applied for the preparation of liposomes 
and polymersomes. They can be classified into methods using organic solvents and 
solvent-free methods. 
In the first case, the membrane building molecules are dissolved in an organic 
solvent and mixed with an aqueous phase. A disadvantage of this method is that the 
solvent which remains in the sample leads to structural defects in the vesicle-forming 
membrane. Therefore, it needs to be extracted using appropriate methods (e.g. 
dialysis, biobeads). 
The second method for polymersome preparation (film-rehydration) concerns the 
formation of vesicles starting from a dry state. The membrane forming material is 
dissolved in organic solvent and dried to a thin film at the inner surface of a vial. By 
further addition of an aqueous phase and application of mechanical energy (e.g. 
stirring) polydisperse vesicles are formed. 
The polydispersity of the aggregates can be decreased by the application of further 
mechanical stress or force, such as extrusion. Using this technique, the vesicle size 
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and dispersity can be further decreased. For this purpose, the mixture is forced 
through a filter with a defined pore size. The shear force causes the break-down of 
the large vesicles and induces the formation of smaller and more monodisperse 
ones, depending on the filter pore size. 
Another solvent-free method of vesicle preparation is accomplished by addition of 
detergents to a dry film of membrane building polymer. After addition of an aqueous 
phase, the detergent supports the shielding of the hydrophobic blocks from the 
aqueous phase. It is important, that the concentration of the detergent is above the 
critical micelle concentration (CMC)2. The detergent associated to the hydrophobic 
blocks is in equilibrium with the free detergent molecules in solution. By removal of 
the free detergent molecules the equilibrium adjusts, which induces a transition to 
vesicular structures. Several methods are known for removal of detergent, e.g. 
dilution [25] or biobeads [26]. 
1.1.6 Methods of characterization 
Colloidal systems such as polymersomes can display variations in membrane 
properties and particle size and structure. Therefore methods for characterization are 
needed to evaluate particle size, number of lamellae, membrane formation and 
thickness. Especially the properties of the membrane are important for many 
applications and need to be known, such as permeability, elasticity, and charge of 
the surface. The most commonly used methods, and applied extensively in this work, 
are: 
                                            
2 The critical micelle concentration is the concentration of surfactants above which micelles are 
spontaneously formed. 
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• Light scattering is a phenomenon which is encountered in everyday life, like 
scattering of light by the particles in the atmosphere giving rise to the color of 
the sky. Light scattering enables the quantitative detection of the average 
particle diameter (z-average) and the polydispersity (PDI) of dispersed 
systems in a range between 5 and 1000 weight average molecular weight. 
The scattering of light by particles is based on their polarizability. Electrons of 
molecules interact with the oscillating electric field of radiation, which is 
inducing a dipole in the molecules which oscillates with the electric field. An 
oscillating dipole is a source of light, therefore the molecules emit scattered 
light, which is of the same wavelength as the incident radiation in the case of 
elastic scattering. 
The intensity of the scattered light is depending on the wavelength (λ) of the 
incident light, the particle size, and the angle at which the scattered light is 
measured. For small particles (λ >> diameter) the Rayleigh-approximation is 
valid. Small particles scatter incident light in all directions with the same 
intensity, which makes the measurement if the intensity of the radiated light 
independent from the angle. In case of bigger particles the intensity of 
scattered light is strongly dependent on the angle- maxima and minima of 
scattered light can be determined. Therefore bigger particles are always 
measured at various angles. 
Due to Brownian motion the particles move freely in solution, inducing 
concentration fluctuations and thus intensity fluctuations of the scattered light. 
These time-dependent fluctuations of the scattered light are detected. The 
movement of the particles is dependent on their size. Small particles move 
faster than bigger ones and therefore emit more scattering signals during time. 
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A monodisperse size distribution of particles in dispersion is unlikely. 
Therefore a complex signal of scattered light is detected and digitalized by an 
correlation software which calculate an autocorrelation function. 
Autocorrelation is a mathematical tool for finding repeating patterns of a signal 
by “comparing” the signal with itself. The autocorrelation function enables to 
extract the diffusion coefficient (D), which is related to the hydrodynamic 
radius (RH) by the Stokes-Einstein equation. [27, 28] 
 
Equation 1 
D- diffusion coefficient [m2s-1], kb- Boltzmann constant [1,38 10-23 JK-1], T- 
temperature [K], η- viscosity [Nsm-2], RH- hydrodynamic radius [m] 
• Transmission electron microscopy (TEM) offers the possibility to visualize 
small objects in the nm size range. Related to vesicles this means, that vesicle 
size and size distribution can be investigated. With an electron microscope, 
much higher resolution can be reached than with a conventional light 
microscope, which is due to the smaller wavelength of electrons compared to 
light. The resolution achieved by electron microscopy is ~2 nm. In electron 
microscopy, a thin film of a sample is transilluminated by electrons and a two-
dimensional picture of the sample can be obtained. During transillumination, 
various interactions between the electron beam and the sample take place. 
Interactions of the electrons with the nuclear envelope of the sample atoms 
cause the electron to emit energy in the wavelength of x-rays (10-12 m). This 
inelastic scattering, which gives spectroscopic information specific to the 
element, is filtered to increase the contrast. In the case of elastic scattering of 
the electrons on the atomic nuclei no energy loss is detected. The scattering 
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intensity of electrons with the atomic nuclei of the sample enables the contrast 
of the picture and increases with the atomic number. Therefore atoms with a 
low atomic number give a lower contrast. In electron microscopy, the sample 
thickness needs to be really low, in order to support the transillumination with 
electrons. In samples containing salt in the buffer solution the evaporation of 
the buffer can lead to local increase in salt concentration, which can cause 
artifacts. As the sample layer is really thin, bigger objects (> 400 nm) are often 
removed with excessive buffer. It should be always kept in mind, that high 
vacuum used in electron microscopy can cause shrinkage of the objects. 
1.2 Drug delivery 
The main function of drug delivery systems is the improvement of the therapeutic 
activity and safety. New therapeutics enter the market, e.g. oligonucleotides, genes, 
peptides and proteins, which have their own macromolecular properties and ask for 
new strategies to overcome physiological and physico-chemical barriers. For 
example, directly related to cancer therapy, such barriers can be (1) high interstitial 
fluid pressure (IFP), (2) reduced oxygen delivery (hypoxia), (3) low extracellular pH 
and (4) apoptosis resistance. Drug delivery systems are needed to maintain or 
change the macromolecular properties of pharmaceutically active compounds to 
overcome these barriers. The delivery of therapeutics by drug delivery systems can 
be an active or passive process. Additionally, drug delivery systems can both 
increase the bioavailability of therapeutics by strategies of controlled release, and 
minimize their adverse effects. Various drug delivery systems derived from the field 
of polymer sciences are continuously proposed to fit with the needs of new 
therapeutics. Their main advantage is the use of synthetic chemistry which allows 
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tailoring the polymers' molecular mass and additional biomimetic behavior, both 
important factors in drug delivery. 
1.2.1 Polymer-conjugate strategies in drug delivery 
Among the techniques used to develop new drug delivery systems, nanotechnology 
based on polymer chemistry, is very promising as it allows the control of polymer 
properties which are important for drug delivery, such as solubility, hydrophobicity 
and molecular mass. In this domain, mainly two systems are usually used: polymer 
conjugates and colloidal systems (micelles, liposomes, nanoparticles). 
Polymer conjugates are often used to shield sensitive biopharmaceuticals such as 
enzymes. Enzymes as “molecular machines” play an important role in many 
metabolic processes in nature. A deficiency of an enzyme can cause profound 
consequences; a well-known example is insulin, which is part of the carbohydrate 
regulating machinery. 
The use of polymer conjugates can efficiently reduce the immunogenicity, and 
therefore prolong the plasma half life, enhance stability and allow passive targeting of 
large molecular weight compounds. Polymer-based medicines have been used 
successfully for the treatment of cancer. Polymer-drug conjugate delivery in cancer 
therapy relies on the “enhanced permeability and retention effect” (EPR effect), a 
property which improves the accumulation of drugs in tumor tissue as compared to 
others.[29] 
For example, covalent coupling of polyethylene glycol (PEG) (Figure 8) to amine 
groups of proteins prevents the proteins from recognition by the immune system. In 
addition, PEG modification facilitates the intracellular uptake of biopharmaceuticals, 
and elevates their intracellular activity. The increase of in vivo lifespan and 
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suppression of the immune response are proportional to the number and length of 
PEG molecules attached to a protein, but excessive modification compromises the 
activity.[30] PEG was shown to prolong the “half-lives” of modified proteins in the 
blood stream from a few minutes to several hours [31, 32] and to be able to 
preferentially localize at sites of inflammation.[33] No adverse side effects of PEG-
modified enzymes have been reported to date.[34] 
 
Figure 8 Chemical structure of poly(ethylene glycol) 
• Another molecule known for its protective effect when used to modify 
biopharmaceuticals is chitosan (Figure 9), a hydrophilic, biocompatible and 
biodegradable polymer of low toxicity. Because of its bioadhesive and 
permeation enhanced properties, chitosan has received substantial attention 
in novel bioadhesive drug delivery systems, as it prolongs the residence time 
at the site of adsorption.[35] Several authors used chitosan-based polymers 
for liposome coating to increase stability towards drug release, or for targeting 
purposes.[36, 37] 
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Figure 9 Chemical structure of chitosan 
1.2.2 Polymeric carriers as a strategy for drug delivery 
The encapsulation of compounds in carriers represents an important  approach used 
in many areas of chemistry, pharmaceutics, and biotechnology. Different strategies 
have been developed and in this respect the use of colloidal systems such as 
micelles, liposomes and nanoparticles is well established.[33, 38, 39] Nevertheless, it 
is still a challenge for scientists to develop new constructs with the desired storage, 
targeting and/or release properties. The use of colloidal systems is characterized by 
the ability to enhance therapeutic activity and to reduce the toxicity of therapeutics, 
mainly by changing their pharmacokinetics and biodistribution. 
Micelles represent a well studied and characterized drug delivery system, broadly 
reviewed in reference [40]. Numerous studies on the application of micelles were 
undertaken.[38, 41-44] The structural characteristics of polymeric micelles, their size 
and core-corona structure have some similarities to natural carriers like viruses and 
lipoproteins. The advantages of using polymeric micelles are (1) the support of long 
circulation, as the uptake by reticuloendothelial systems is lowered, (2) effective 
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prevention of non-specific adsorption of proteins and (3) the solubilization of 
hydrophobic drugs in the micellar core. 
Liposomes as a drug delivery system represent one of the most conventional 
systems to protect biopharmaceuticals from degradation by the immune system. 
They were used in a wide variety of delivery approaches due to their property to 
facilitate intracellular delivery, via fusion with the plasma membrane, receptor-
mediated endocytosis, and phagocytosis.[45] Encapsulation efficiency, size and 
surface (e.g. charge and rigidity) properties of the liposomes can be varied by the 
lipid composition and the preparation method. A various number of different 
preparation methods were tested for the encapsulation of proteins: dehydration- 
rehydration method,[46, 47] hydration of thin lipid film method,[47, 48] injection 
method,[49] reverse-phase evaporation and freeze-thawing method.[47] Different 
methods and lipid compositions give liposomes with different size distributions, 
lamellarity, encapsulation efficiencies and biological affinities. Modification of the 
outer surface of the liposomes with stealth and targeting moieties (e.g. PEG, 
chitosan) allows for their life span to be extended in vivo. 
However, there are certain drawbacks of liposomes supporting the progress in 
polymer science, such as toxicity of cationic liposomes,[50, 51] structural defects 
causing leakage,[52] mechanical instability,[53] interactions with high-density 
lipoproteins,[54] and short blood circulation lifetime.[55] 
• One of the most promising approaches for the design of drug delivery systems 
is the bottom-up design of polymeric systems using self-assembly 
mechanisms.[8, 56, 57] More than the liposomal systems, the use of polymeric 
carriers offers the control of physical and chemical properties, by changing the 
block length-ratio, or by introduction of functional groups. This makes them 
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more versatile for a wider range of applications.[58] In several studies, the 
mechanical properties of polymersome- and phospholipid membranes, such 
as area elastic and bending moduli, were compared and shown that 
polymersomes in the fluid state can be designed to be 5-50 times tougher than 
liposomes.[8] 
A number of methods for the preparation of polymeric drug carriers are available. 
The selection of the method mainly depends on the chemical properties of the drug 
which needs to be formulated, hence for formulation of biomolecules, such as 
enzymes, solvent free methods are the first choice. For more hydrophobic molecules 
solvent-containing preparation methods can be used. All the methods follow the 
basic principle of vesicle preparation introduced in paragraph 1.1.5. In reference [59] 
a multitude of different methods for the formulation of biomolecules is discussed. 
Only a few general considerations for the selection of a specific preparation method 
are given at this point. 
1.2.3 Directing pharmaceutically active compounds 
Besides the need to maintain the stability and increase the bioavailability of 
pharmaceutical compounds, there is the need to deliver them to their specific site of 
action. Targeting can help lower the concentration of the administered drug as less 
drug is spreading in the organism, and therefore to decrease the probability of 
adverse effects. Two main strategies for the direction of drugs can be distinguished: 
passive and active targeting. 
The passive targeting is accomplished by the properties of the carrier system and 
can be integrated during their design. 
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One example of passive targeting is the “enhanced permeability and retention” effect 
(EPR effect), which is connected to the use of polymer-drug conjugates. These 
conjugates showed enhanced bioavailability in vivo and a preferred uptake by 
carcinogenic tissues. 
Another passive targeting approach is based on the use of stimuli-responsive 
systems. One example of passive targeting can be the use of pH-responsive carriers. 
Various diseases can cause changes in the pH in the near microenvironment. The 
pH-sensitive bonds, especially designed for polymer-drug conjugates can react on 
this change and cause the drug release. 
Another way is to use thermosensitive carrier systems, which can mediate the 
release when temperature is increased above the phase transition temperature.[60] 
Thermally responsive drug-polymer conjugates were used to target solid tumors, due 
to the effect of hyperthermia.[61] In this approach, the carrier had lower critical 
solution temperature (LCST) between body temperature and the temperature in a 
tumor. This enables thermally targeted drug delivery by enhancing the localization of 
the thermally responsive drug carrier. 
Active targeting is mostly accomplished by receptor-mediated delivery or the use of 
other biomolecules with highly specific affinity. For the receptor-mediated delivery, a 
specific ligand molecule, recognized by the receptor, is conjugated to a drug or a 
carrier. The conjugation of functional groups to the surface of polymersomes can be 
directly implemented in their design.[62] Antibodies directed against endothelial 
surface determinants, small antigen-binding fragments of these antibodies [62] and 
short peptidic signal sequences [19] represent the most useful approaches of surface 
modification of polymeric carriers. By binding of the ligand molecule to the receptor 
the process of internalization starts.[18] 
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Antibodies are naturally occurring biomolecules which help the body to fight infection. 
They can be exploited to target drugs to their site of action in the organism. 
Antibodies can be raised against a wide variety of proteins on the surface of tissues. 
Those surface proteins have several functions, important to maintain the metabolism 
of the tissue, but they can also serve as an indicator for diseases. Some diseases 
can cause changes of extracellular proteins exposed on the surface of the cell. When 
these changes are known, antibodies specific against these changed surface 
proteins can mediate drug targeting.[62] 
1.2.4 Targets for drug delivery 
The endothelium belongs to one of the most important therapeutic targets in living 
organism. The endothelium is the thin layer of cells which lines the interior surface of 
the blood vessels, forming an interface between circulating blood in the vessel and 
the vessel wall. Endothelial cells cover the whole interior surface of the circulatory 
system, from the heart to the smallest capillary. The endothelial cells are involved in 
important regulatory processes, e.g. vasoconstriction and vasodilation (control of 
blood pressure), thrombosis and fibrinolysis (control of blood clotting), 
atherosclerosis (chronic inflammatory disease in the wall of arteries) and 
inflammation. Table 1 shows selected candidate targets for drug delivery to 
endothelial cells. Furthermore the endothelium represents a barrier for drug delivery 
systems to reach the tissues beyond the vascular wall. Drug delivery systems with 
specific affinities, compatible with the endothelial binding sites, are needed to 
enhance the targeting and mediate internalization. Those specific affinities can be 
antibodies against endothelial surface proteins (Table 1). By binding to endothelial 
surface, proteins and receptors often cause internalization. The pathway for 
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internalization and possible transfer to other tissues is mainly dependent on the 
binding site / receptor. A summary of endocytic pathways is given in Figure 10. There 
are various pathways of internalization available in endothelial cells, such as clathrin- 
and caveoli-mediated endocytosis, phagocytosis, macropinocytosis and cell 
adhesion molecule (CAM) mediated endocytosis. The metabolism and effects of 
internalized drugs largely depend on the routes of intracellular trafficking, which may 
lead to degradation in lysosomal compartments, recycling to the plasma membrane 
or transcytosis to the basal surface of the endothelium. 
Table 1 Selected candidate targets for drug delivery to endothelial cells. (EC- 
endothelial cells, ACE- angiotensin-converting enzyme, TM- thrombomodulin, 
PECAM- platelet-endothelial adhesion molecule, ICAM- intercellular adhesion 
molecule, gp- glycoproteins) 
Target Function and 
Localization 
Targeting Advantages Potential Problems 
ACE Peptidase, converts 
Ang I to Ang II and 
cleaves bradykinin. 
ACE enriched in the 
lung capillaries. 
Selective targeting to 
lung EC. Intracellular 
delivery. Vasodilating 
and anti-inflammatory 
effects of ACE-
inhibition. 
Inflammation 
suppresses targeting. 
ACE inhibition may be 
dangerous. 
TM Binds thrombin and 
converts it into an 
anticoagulant 
enzyme. 
Intracellular delivery to 
EC, useful for modeling 
of lung injury in animals. 
Inflammation 
suppresses targeting. 
Thrombosis due to TM 
inhibition. 
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Figure 10 Summary of endocytic pathways. 
Another very attractive target for drug delivery are mitochondria, which are 
membrane-enclosed organelle found in most eukaryotic cells. They can be described 
as “cellular power plants”, because they generate most of the cells' supply of 
adenosine triphosphate (ATP), used as the source of chemical energy. In addition, 
they are involved in a range of other processes such as metabolism, programmed 
(apoptotic) cell death, Ca2+ homeostasis, and cell signaling, control of cell cycle and 
cell growth.[63] Mutations in mitochondrial DNA are associated with a range of 
human diseases, again making mitochondria attractive targets for mitochondrial gene 
therapy. 
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1.2.5 Polymeric application in drug internalization 
During the last decade, intracellular drug delivery has become an emerging area of 
research in the medical and pharmaceutical field. Many therapeutic agents such as 
drugs and DNA/oligonucleotides can be delivered not just to the cell but also to a 
particular compartment of a cell in order to achieve better activity, e.g. proapoptotic 
drugs to the mitochondria, antibiotics and enzymes to the lysosomes and various 
anticancer drugs and genes to the nucleus.[64] Therefore, targeting to the 
appropriate cell is not enough for therapy involving drugs acting intracellularly. 
Polymeric drug delivery systems can support cellular uptake by pinocytosis (clathrin-
coated pits, caveoli, macropinocytosis), adsorptive endocytosis and receptor 
mediated endocytosis (Figure 10). The uptake of the polymeric systems depends on 
physicochemical properties i.e. surface charge, size and presence of a specific ligand 
for the cell surface receptor. Due to smart design of polymeric delivery systems, all 
these factors can be adopted to specific applications. A protruding function of 
polymeric carriers is the mediation between the chemical properties of the drug and 
the internalization pathway. It is known that the plasma membrane is the major 
obstacle for large and charged molecules. The biological membrane is also 
responsible for the compartmentalization of cellular organelles and acts as a natural 
barrier for most molecules. Therefore, the transportation through this barrier is a 
fundamental requirement for drug delivery systems. There are various factors which 
are responsible for the rate of diffusion through membranes, such as the size and 
hydrophobicity of the diffusing molecules.[65] Thus, the biological membrane 
prevents the entry of hydrophilic molecules. Eukaryotic cells use a number of 
different endocytotic mechanisms to transport macromolecules and carriers over the 
plasma membrane barrier (Figure 10). The challenge in the design of drug delivery 
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systems is therefore to mask the chemical properties of the drug in order to target it 
inside the cells. Even after the drug has crossed the biological membrane, other 
problems can occur. Currently, a major challenge is to manipulate or circumvent the 
non-productive trafficking pathways, such as routing of drugs, proteins and DNA to 
the lysosomes where they are degraded. Drugs, which are internalized by endocytic 
pathways and are not stable at endosomal or lysosomal pH, must bypass the 
endocytic pathway in order to have an efficient activity in the cytosol or at cell 
organelles.[66] 
A novel approach to transfer molecules directly to the cytosol, circumventing the 
endocytic pathway, is by using cell-penetrating peptides (CPP's). An advantage to 
use polymeric nanocontainers is that they can be functionalized with cell-penetrating 
peptides, which mediate the uptake of cargos of different size into cytosol. Cell 
penetrating peptides have been derived from viral proteins, such as VP22 [67, 68] 
and HIV-TAT (transactivator of transcription) [69, 70] to novel chemically designed 
peptides such as poly-arginine.[71, 72] Despite the variability in their origins, these 
compounds are all capable of crossing biological membranes and carrying the cargo 
into cells.[73] 
TAT and other CPP`s were been shown to deliver cargoes as large as iron 
nanobeads and fluorescent quantum dots into cells in culture.[74, 75] TAT has also 
been used to deliver large, active proteins into cells and TAT fusion proteins, to treat 
cancer, inflammation and other diseases,[76, 77] to deliver phage-encapsulated DNA 
to cells, and liposome-encapsulated DNA for gene expression in mice.[78, 79] It 
should also be noted that the efficiency of transduction of TAT and other CPPs 
depends greatly on the cargo being transduced; this principle is most clearly 
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demonstrated by difficulties in transducing large, anionic cargo like nucleic acids.[80-
83] 
The diversity of studied CPP’s allows choosing an internalization pathway when 
designing a drug carrier. Simply altering the oligopeptide by the attachment of 
molecules changes the internalization pathway depending on the size and 
hydrophobicity, and therefore affects the efficiency of the delivery system for 
cytosolic or nuclear targeting.[84, 85] Furthermore, the followed pathway governs the 
intracellular processing, kinetics and final fate of the CPP and its cargo, and is 
dependent on several factors including the type of the CPP, type of the attached 
cargo, the nature of the linkage between the cargo and CPP and the cell system. 
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2 Oxidative stress and strategies to diminish it 
2.1 Oxidative stress 
Oxygen, which is essential for the survival of aerobic organisms, can also be harmful 
to their existence. Oxidative stress is the imbalance between radicals derived from 
oxygen, and the organism's antioxidant defense mechanism. A “radical” is defined as 
any atom or biomolecule that contains unpaired electrons. These unpaired electrons 
influence the chemical reactivity, making the radical more reactive than the 
corresponding non-radical. The biologically relevant radicals are the superoxide 
anion (O2•–), the hydroxyl radical (OH•) and nitric oxide (NO•). Under normal 
conditions, around 1 to 3 % of the oxygen that is metabolized in the mitochondria is 
converted to the O2•– radicals. Some other species are intermediate in the 
metabolism of O2 or NO but are not radicals. These intermediate species along with 
the radical species are called reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), respectively. The most known example of ROS is hydrogen peroxide 
(H2O2), and of RNS it is peroxynitrite (ONOO–). 
The toxic effect of oxidative stress for tissues is based on the reactivity of ROS' with 
cellular macromolecules, such as proteins, carbohydrates, lipids, and nucleic acids. 
Exogenous agents like photochemical smog, ozone, pesticides, xenobiotics and 
ionizing radiation, as well as a variety of endogenous processes, such as 
mitochondrial respiration, cytochrome P-450 detoxification reactions, phagocytic 
oxidative bursts, and peroxisomal leakage, can generate significant amount of ROS. 
ROS have been implicated in aging and [86] various pathological disorders, including 
cancer, atherosclerosis, rheumatoid arthritis, lupus erythematosus, chronic 
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inflammatory diseases of the gastrointestinal tract, cataract, diabetes, diabetic 
retinopathy, Parkinson’s disease, Alzheimer’s disease.[87-89] In fact, the ability to 
cope with ROS decreases with age. A wide variety of antioxidant defense systems, 
enzymatic as well as nonenzymatic, help to prevent and repair ROS-induced damage 
to tolerable levels. Under ideal circumstances, the rate of production of an 
oxidatively-modified cellular component should be comparable to that of its removal 
or repair. 
2.2 Natural defense mechanism against oxidative stress 
Oxidative stress appears in many pathological conditions, such as inflammation, 
cancer, aging and organ response to ischemia-reperfusion as a result of modern 
transplantation techniques or diseases. Although oxidative stress in low 
concentration has an important role as mediator in normal cellular metabolism and 
signal transduction, in higher concentrations it can be damaging. Therefore in 
mammalian cells there exists a complex defense mechanism, which exhibits an 
antetype for researchers, who try to build artificial defense mechanisms. 
Antioxidant substances are defined as substances that significantly delay or prevent 
oxidation of the substrate when they are present at low concentrations compared to 
those of oxidizable substrate. The members of the natural antioxidant defense 
mechanism are mainly small molecular weight substances and enzymes that can 
convert and detoxify oxidative stress. 
The antioxidant defenses include the superoxide dismutase, catalase, gluthatione 
peroxidase and reductase enzymes, the tripeptide gluthatione, the polypeptide 
thioredoxine, and peroxidases of the peroxiredoxin family. 
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As an example, we show the detoxification of O2•– radicals in the body, via cascade 
reactions in which SOD, catalase or gluthatione peroxidase are involved. In the first 
step, SOD catalyses the dismutation of superoxide to hydrogen peroxide and oxygen 
(Equation 2). 
2  O2•–  +  2  H+  →  H2O2  +  O2 Equation 2 
The product of Equation 2, H2O2, is a weak oxidant and is relatively stable. In the 
second step, three main systems can break down H2O2: catalase, gluthatione 
peroxidase and peroxidases of the peroxiredoxin family3. 
Hemoprotein catalase, present in all major body organs, is especially concentrated in 
the liver. It catalyzes the breakdown of hydrogen peroxide to oxygen and water 
(Equation 3). 
2  H2O2  →  O2  +  2H2O Equation 3 
The second system consists of the gluthatione peroxidase, which removes hydrogen 
peroxide generated by superoxide dismutase by the oxidation of gluthathione (GSH) 
to its oxidized form, gluthatione disulphide (GSSG) (Equation 4). 
2  GSH  +  H2O2  →  GSSG  +  2H2O Equation 4 
GSH is a tripeptide present in millimolar concentration in almost all cells, and 
represents an important component of the endogenous antioxidant system. Its main 
function is to act as a co-substrate for gluthatione peroxidases. 
The third system consists of peroxidases of the peroxiredoxin family, that reduce 
hydrogen peroxide to water and alcohol by using reducing equivalents. Thioredoxin is 
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a polypeptide especially concentrated in the endoplasmatic reticulum, but also found 
in the mitochondria. In its reduced form it contains two adjacent sulfhydryl groups that 
are converted to a disulphide in its oxidized form thioredoxin. 
Besides various enzymes with protective role, there are various low-molecular-weight 
molecules that have in vivo antioxidant properties, such as bilirubin, melatonin, lipoic 
acid, coenzyme Q, uric acid and melamines.[90-93] A large number of dietary 
constituents exhibit antioxidant effects in vivo, as for example ascorbic acid (vitamin 
C), or carotenoids. Vitamin C is an important component of the antioxidant system in 
humans, which acts as a reducing agent, and can therefore scavenge radicals such 
as O2•–. Carotenoids represent a group of colored pigments widespread in plant 
tissues and which serve as precursors for vitamin A. As a principal dietary source of 
vitamin A in humans, they exert an antioxidant action as free radical scavengers.[94] 
2.3 Antioxidant therapy 
Antioxidant therapy represents an adaptive treatment directed to the down-regulation 
of excessive oxidative stress. In this respect, several substances, known as 
members of the natural antioxidant defense mechanism (see 2.2) are applied to 
reduce the amount of oxidative stress, e.g. catalase or superoxide dismutase. The 
main problem with proteinogenic antioxidants is their short half-life in the plasma, and 
the difficulty of protein uptake by the cells. To bypass these difficulties, targeted 
catalase derivatives were developed by conjugation with carbohydrates. The initial 
results appear promising.[95] 
The rationale behind using SOD is to accelerate the detoxification of the superoxide 
anion, thus preventing the generation of highly reactive OH• radicals. In vivo studies 
reported protective effects with SOD treatment,[96, 97]  but as its cellular penetration 
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is poor, this strongly affects and limits its therapeutic potential.[98] Like catalase, the 
main problem of SOD administration is its short half-life (about 6 min) and the lack of 
uptake into cells. In most animal studies, protective effects of SOD required multiple 
or prolonged intravenous infusions of 10-150 mg/kg body weight to reach a 
therapeutic effect.[99-105] However, the treatment by SOD seems to be a promising 
alternative to conventional therapies and therefore various attempts were made to 
improve its biocompatibility.[106, 107] To improve the intracellular availability of SOD, 
conjugates of SOD were applied, e.g. after PEGylation.[108] Conjugation of proteins 
with high molecular-weight poly(ethylene glycol) is known to support the uptake of 
the conjugates into the cell, however the delivery of drugs to sites of increased 
oxidative stress is needed to increase the efficiency of the artificial antioxidant 
defense mechanism. 
2.3.1 Superoxide dismutase 
Copper-zinc superoxide dismutase (CuZnSOD) is a 32 kDa homodimeric protein in 
the cytoplasm of eukaryotic and bacterial cells that catalyzes the disproportionation 
of superoxide into oxygen and hydrogen peroxide (Equation 2).[109] Three forms of 
SOD exist with different subcellular localizations. Those containing copper and zinc 
are located in the cytosol, [110] while the manganese form is located in the 
mitochondria, [111] and the extracellular form usually is present outside the plasma 
membrane and interacting with the matrix components. 
In CuZnSOD, each monomer binds one copper and one zinc ion and displays the 
Greek Key β-barrel fold.[112] The enzymatic mechanism proposed for CuZnSOD is 
the reduction of the oxidized Cu(II) form of the enzyme by superoxide and the 
release of oxygen (Equation 5). 
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O2•–  +  Cu(II)ZnSOD  →  O2  +  Cu(I)ZnSOD Equation 5 
This process is followed by the oxidation of the reduced Cu(I) form by another 
superoxide anion and two protons, generating hydrogen peroxide (Equation 6).[113-
116] 
O2•–  +  Cu(I)ZnSOD  +  2  H+  →  H2O2  +  Cu(II)ZnSOD Equation 6 
The catalytic cycle of CuZnSOD is summarized in Figure 11 and can be described as 
following. The CuZnSOD molecule is situated in the “resting state” (Figure 11-A), with 
the copper ion in a distorted square planar conformation. The second step of the 
cycle can be described as SOD inner sphere transfer state (Figure 11-B). Superoxide 
is guided to the active site channel by a conserved set of charged amino acid 
residues. The channel containing these charges narrows from a shallow depression 
about 24 Å across to a deeper channel about 10 Å wide and finally to a size of less 
than 4 Å just above the copper ion. An arginine residue at the entrance of the 
channel helps to attract negatively charged molecules. O2•– enters the active site 
channel, displaces a water molecule situated there, and an electron is released after 
binding to the copper ion. In the third state (Figure 11-C), the histidine bridge breaks, 
oxygen diffuses out of the active site channel, and a water molecule enters. The 
copper is now in a trigonal planar conformation characteristic of Cu(I). In the fourth 
step (Figure 11-D) a second superoxide enters the active site cavity, displaces a 
water molecule and hydrogen bonds with the second water molecule and a 
protonated atom of His63. In the final step (Figure 11-E) superoxide accepts an 
electron from copper and protons from a water molecule and His63 to from hydrogen 
peroxide. Peroxide diffuses out of the active site and is replaced by a water molecule. 
The bridge between zinc and copper via His63 is reformed.[117] 
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Figure 11 Schematic diagram of the catalytic cycle of CuZnSOD (see paragraph 
2.3.1) 
 50 
 
 
Figure 12 A) Ribbon diagram of reduced homodimeric Cu-Zn SOD (PDB#1SXA) 
[118].The metal ions are drawn as spheres. B) Enlargement of the SOD active site. 
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Copper is drawn as blue sphere liganded by His 61, 46, 118, and 44. Zinc is drawn 
as red sphere liganded by His 78, 61, 69, and Asp 81. 
As the active site in CuZnSOD is located in the metal-binding region, several studies 
were performed to characterize it. Crystallographic and spectroscopic studies 
showed that the histidine residue 61 (bovine erythrocytes SOD: His63) coordinates 
the copper and zinc ions (Figure 12). This histidine residue is described as a 
“histidine bridge”, a motif only known in CuZnSOD. The copper binding geometry is 
described as distorted square planar, as the residues His63, His48, His120 and 
His46 (bovine erythrocytes SOD: His61, His48, His118, His46) build up this 
geometric form around the copper ion. 
2.4 An antioxidant nanocontainer 
In this work we designed an antioxidant nanoreactor based on the encapsulation of 
CuZnSOD in amphiphilic copolymer nanovesicles (Figure 13). The nanovesicles are 
formed by self-assembly of amphiphilic copolymer poly-(2-methyloxazoline)-poly-
(dimethylsiloxane)-poly-(2-methyloxazoline) (PMOXA-PDMS-PMOXA). We chose 
this polymer due to its advantages over conventional systems, i.e. liposomes. 
Polymer nanocontainers can be produced with a controlled mean diameter and low 
polydispersity compared to liposomes. They were tested and shown to be more 
stable than liposomes.[1] These represent the main advantages with respect to the 
application as carriers to improve the drug stability and the circulation life-time. 
Another factor which could increase dramatically the circulation life-time and 
therefore the availability of the encapsulated SOD, is the stealth property of the poly-
(2-methyloxazoline) chain, comparable to that of PEG. Besides, the polymer used for 
this study, has an oxygen permeable membrane, as will be shown later. All these 
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advantages make the nanoreactors a completely new approach of drug delivery 
systems, in which the cargo is not released, but performs its function within the 
vesicle. 
The nanovesicles, made of poly-(2-methyloxazoline)-poly (dimethylsiloxane)-poly (2-
methyloxazoline), successfully encapsulated the SOD protein during their formation 
by a self-assembling process, as proved by confocal laser-scanning microscopy and 
fluorescence-correlation spectroscopy. Electron paramagnetic resonance 
spectroscopy and circular dichroism analyses showed that no structural changes 
appeared within the proteins once inside the inner cavity of the nanovesicles. The 
function of this antioxidant nanoreactor was tested by pulse radiolysis which 
demonstrated that superoxide dismutase remains active inside the nanovesicles. 
This simple and robust hybrid system provides selective shielding of a sensitive 
enzyme from proteolytic attack and therefore points to a new direction for developing 
drug delivery applications. 
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Figure 13 A schematic representation of an antioxidant nanoreactor with 
encapsulated SOD. The O2•– is able to penetrate the polymeric shield. 
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3 Antioxidant nanoreactor based on SOD encapsulation in 
polymersomes 
3.1 The polymersomes – preparation and characterization 
3.1.1 Nanocontainer preparation 
The synthesis of PMOXAn-PDMSm-PMOXAn (where n = 15 and m = 110), was 
described elsewhere.[119] Nanovesicles were prepared according to a modification 
of a previously published method.[120] Triblock copolymer PMOXA15-PDMS110-
PMOXA15 (50 mg) was dissolved in ethanol at 17 % (w/w) and stirred at room 
temperature for 1 hour. After complete dissolution, this solution was slowly added 
dropwise to PBS buffer to give a final polymer concentration of 10 mg/ml, and this 
mixture was stirred overnight at room temperature. The solution was then extruded 
20 times through a polycarbonate membrane filter (Millipore) with a well-defined pore 
size of 200 nm, in order to decrease the size polydispersity of vesicles.[120] 
Subsequently, the extruded solution was purified by size-exclusion chromatography 
(SEC) on Sepharose 4B (10 × 300 mm). The nanostructures were characterized by 
TEM, SLS, and DLS. 
3.1.2 Characterization of polymersomes 
Transmission electron microscopy was used to image empty and SOD-containing 
polymersomes. Nanovesicle dispersions were negatively stained with 2 % uranyl 
acetate solution and deposited on a carbon-coated copper grid. The samples were 
examined with a transmission electron microscope (Philips Morgagni 268D) at 293 K. 
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TEM of self-assembled nanostructures of polymer shows circular objects with radii 
ranging from 50 to 110 nm, in good agreement with results obtained from cryo-TEM, 
which indicated nanovesicles with a radius of 117 nm. TEM measurements repeated 
after long-term storage (> 3 weeks) [119] at 4 °C did not reveal any significant 
changes, suggesting that the nanovesicles from PMOXA15-PDMS110-PMOXA15 are 
chemically stable. 
Dynamic (DLS) and static (SLS) light-scattering experiments were performed on a 
ALV (Langen, Germany) goniometer, equipped with an ALV He-Ne laser (λ = 632.8 
nm) to determine the sizes and size distribution of empty and SOD-containing 
polymeric nanovesicles. SOD-encapsulated and empty nanovesicles were prepared 
by serial dilution to polymer concentrations ranging from 3.33 to 0.1 mg/mL. Light 
scattering was measured in 10-mm cylindrical quartz cells at angles of 30–150 ° at 
293 K. The data for DLS were analyzed using a Williams-Watts function.[121] The 
size polydispersity of the vesicles was determined according to the literature.[1, 28, 
122] 
The LS results are presented in Table 2. We calculated a ratio (ρ = Rg/RH) of the 
radius of gyration (Rg), obtained from SLS, to the hydrodynamic radius (RH), from 
DLS experiments of 0.96, which is characteristic for hollow spherical objects. This so 
called ρ-parameter is a structure-sensitive property reflecting the radial density 
distribution of the scattering particle.[123] Based on the assumption of a one-
component population, the mean radius of these vesicles is about 150 nm. This 
larger value, compared to the value obtained from electron microscopy, is due to the 
fact that in DLS the RH represents the sum of the particle and its surrounding 
hydration sphere. 
 56 
 
Table 2 Light scattering characterization of empty vesicles 
sample Rg [nm] RH [nm] M [108g/mol]a A2 [mol/L/g2]b 
empty vesicles 150 ± 7 156 ± 8 4.7 ± 0.1 5.1×10-11 
a M, weight-average molar mass; b A2, second virial coefficient. 
 
Figure 14 Zimm plot of polymer vesicles without encapsulated SOD. 
3.2 SOD Encapsulation: method, efficiency, stability 
3.2.1 Fluorescent labeling of SOD 
Fluorescently labeled SOD was obtained by reaction of a fluorescent dye, Alexa 
Fluor 488, with the primary amines of the protein. Labeled SOD was separated from 
unbound Alexa Fluor 488 by SEC on Sephadex G50 (10 × 300 mm) equilibrated with 
phosphate-buffered saline (PBS) buffer. The concentration of labeled protein in 
solution was determined by pulse radiolysis.[124] The number of Alexa Fluor 
488/SOD molecules was determined by fluorescence correlation spectroscopy. 
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3.2.2 Encapsulation of fluorescently labeled SOD in nanovesicles 
Encapsulated SOD was obtained by adding the polymer solution as described above 
to a solution of labeled SOD (0.26 mg/ml) in PBS buffer. The non-encapsulated 
protein was removed by size exclusion chromatography on a Sepharose 4B column, 
in PBS buffer eluent. To determine whether the protein can be attacked from the 
outside of the vesicles, a stock solution of 20 mg/ml of Proteinase K (Roche) was 
added to the solution of encapsulated, fluorescently labeled SOD at 5 % (v:v), and 
the mixture was incubated for 4 hours at room temperature. 
3.2.3 Characterization of SOD-encapsulating polymersomes 
Nanovesicles with encapsulated SOD were characterized by TEM and LS (as 
described above), and were compared with the empty vesicles. TEM images for 
SOD-containing nanovesicles (Figure 15) were essentially identical to those for 
empty vesicles. From SLS and DLS experiments we find a ρ-value of 0.93. The LS 
characterization of SOD-containing vesicles is presented in Table 3 and Figure 16. 
Compared to the LS results for empty vesicles (Table 2), SOD containing vesicles 
show only a minor difference of Rg and RH. The differences of the values are within 
the error range. 
 58 
 
 
Figure 15 Transmission electron micrograph of SOD-encapsulated in PMOXA15-
PDMS110-PMOXA15 vesicles (room temperature; scale bar = 100 nm) 
Table 3 Light scattering characterization of SOD-containing vesicles 
sample Rg [nm] RH [nm] M [108g/mol]a A2 [mol/L/g2]b 
SOD-containing 
vesicles 
140 ± 10 149 ± 9 3.4 ± 0.1 1.3×10-11 
a M, weight-average molar mass; b A2, second virial coefficient. 
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Figure 16 Zimm plot of polymer vesicles with encapsulated SOD. 
To check the stability of the nanovesicles containing SOD, they were re-analyzed by 
LS after 3 weeks of storage at 4 °C; the LS measurements did not indicate any 
change in radius or size distribution of the nanoreactors over time. This level of 
stability was expected because of the tightness of the polymer membrane.[1, 125] 
All these results indicate that the encapsulation of SOD during the self-assembly 
process does not influence nanovesicle formation in terms of size or stability. 
3.2.4 Laser-Scanning Microscopy/ Fluorescence-Correlation Spectroscopy 
To investigate whether the protein is located in the inner space of the nanovesicles, a 
configuration essential for its shielding, we analyzed nanovesicles prepared with 
encapsulated SOD, labeled with the fluorescent probe Alexa Fluor 488, by confocal 
laser scanning microscopy (CLSM) and fluorescence correlation spectroscopy (FCS). 
Laser scanning microscopy (LSM) and fluorescence correlation spectroscopy (FCS) 
measurements were performed on a Zeiss LSM 510-META/Confcor2 laser scanning 
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microscope equipped with an argon laser (488 nm) and a 40× water-immersion 
objective (Zeiss C/Apochromat 40X, NA 1.2), with the pinhole adjusted to 70 μm. 
Solutions of polymeric nanoreactors (2–3 mg/ml) with encapsulated SOD-Alexa Fluor 
488 were measured at room temperature in special chambered quartz glass holders 
(Lab-Tek; 8-well, NUNC A/S), which provide optimal conditions for imaging while 
reducing evaporation of the aqueous solutions. In LSM mode, appropriate filters were 
chosen and the detector gain, amplifier gain, and offset were adjusted to optimize 
micrograph quality; images (512 × 512 pixels) were collected with a scan speed of 
0.96 s/pixel at 8-bit color depth. In FCS mode, intensity fluctuations were analyzed in 
terms of the autocorrelation function with the LSM 510/Confocor software package 
(Zeiss, AG). Spectra were recorded over 30 s, and each measurement was repeated 
ten times; results are reported as the average of three independent experiments. 
Adsorption and bleaching effects were reduced by exchanging the sample droplet 
after 5 minutes of measurement. The excitation power of the Ar laser was PL = 
15 mW, and the excitation transmission at 488 nm was 2 %. To reduce the number of 
free fitting parameters, the diffusion times for free dye (Alexa Fluor 488) as well as 
the labeled SOD were independently determined and fixed in the fitting procedure. 
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Figure 17 A CLSM micrograph of SOD-Alexa Fluor 488 encapsulated in PMOXA15-
PDMS110-PMOXA15 polymeric nanovesicles 
We used FCS to examine in more detail the encapsulation of SOD in nanovesicles, 
by measuring free Alexa 488, non-encapsulated SOD-Alexa Fluor 488, and 
encapsulated SOD-Alexa Fluor 488. In FCS, a fluctuation correlation approach is 
applied, in which the laser-induced fluorescence of the excited fluorescent molecules 
that pass through a very small probe volume is auto-correlated in time to give 
information about the diffusion times of the molecules. According to the Stokes-
Einstein equation, the diffusion times, which are proportional to the RH of the 
fluorescent molecules, provide information about interactions of the fluorescent 
molecules with larger target molecules, including encapsulation of protein in 
nanovesicles.[122] The results are presented in Figure 18; autocorrelation 
amplitudes are normalized to 2 to facilitate comparison of diffusion times and the 
shapes of the curves. The diffusion time (τd) for free Alexa Fluor 488 at room 
temperature is 23 μs (Figure 18, curve a). For non-encapsulated SOD-Alexa Fluor 
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488, τd = 104 μs, which corresponds to RH = 2.4 nm, in good agreement with the 
radius of 2.2 nm calculated on the basis of the molecular mass (33 kDa) of SOD-
Alexa Fluor 488 (Figure 18, curve b). For encapsulated SOD-Alexa Fluor 488, the 
multiphasic curve (Figure 18, curve c) indicates the presence of slowly diffusing 
particles. This population with a reduced diffusion (τd = 2.3 ms) represents more than 
78 % of the total number of fluorescent particles that pass the confocal volume during 
the measurement time of 30 s, and corresponds to vesicles that encapsulate SOD-
Alexa Fluor 488.  
 
Figure 18 FCS autocorrelation curves. a) Solution of Alexa Fluor 488 (4x10-6 mg/ml) 
in PBS buffer, b) Solution of SOD-Alexa Fluor 488 (6x10-6 mg/ml) in PBS buffer, and 
c) Solution of SOD-Alexa Fluor 488 encapsulated in polymeric nanovesicles from 
PMOXA15-PDMS110-PMOXA15 
FCS measurements were also used to investigate the stability of polymeric 
nanovesicles encapsulating SOD. After 3 weeks of storage at 4 °C samples were re-
analyzed and no release of SOD could be detected. 
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3.2.5 Estimation of the number of SOD molecules inside the nanovesicles 
To estimate the number of SOD molecules encapsulated in the nanovesicles, we 
compared the molecular brightness, reported as count rates per molecule (cpm, in 
kHz) of free Alexa Fluor 488, non-encapsulated SOD-Alexa Fluor 488, and 
encapsulated SOD-Alexa Fluor 488. 
We found that one Alexa Fluor 488 is attached to one SOD molecule using a 
calibration curve of molecular brightness as the function of known concentrations of 
Alexa Fluor 488 (Figure 19). 
SOD-Alexa Fluor 488 in the presence of a polymer environment exhibited less 
molecular brightness (cpm = 27 kHz) than free Alexa Fluor 488 (cpm = 42 kHz), the 
difference being mostly attributed to quenching of the dye.[126] 
 
Figure 19 Calibration curve of molecular brightness of free Alexa Fluor 488. 
In the case of encapsulated SOD-Alexa Fluor 488, the total molecular brightness 
(cpmT) corresponds to the weighted sum of the brightnesses of the individual 
components (cpmi) (Equation 7). 
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Equation 7 
cpmT – total molecular brightness, cpmi – individual molecular brightness, ai – 
proportion of i in the total core solution. 
By comparing the molecular brightness of the encapsulated SOD-Alexa Fluor 488 
solutions with that of the free labeled protein in the presence of polymer, we estimate 
that an average of 2-5 SOD-Alexa Fluor 488 molecules are encapsulated per 
nanovesicle when the initial concentration of SOD-Alexa Fluor 488 was 0.1-0.27 
mg/ml. This is in agreement with the average number of encapsulated SOD 
molecules that can be calculated from the initial concentrations of SOD together with 
the total volume of the inner spaces of the vesicles. The inclusion is a statistical 
process in which the number of encapsulated molecules is determined by the starting 
concentrations of the protein. Under the experimental conditions applied, the number 
of encapsulated SOD molecules is small, as we intended to minimize interactions 
and functional changes due to confinement in the nanovesicles. In addition, by 
encapsulating only a small number of SOD molecules we tested the sensitivity of the 
nanoreactor, a prerequisite for further therapeutic applications. Studies of enzymes at 
the level of one molecule have the potential to provide significant insight into the 
detailed spectrum of molecular conformational changes and activities.[127-130] 
The block copolymer membranes can be regarded as mimetics of biological 
membranes, but they are thicker and far more stable than those of the liposomes.[1, 
125] 
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3.3 Selective shielding of SOD from proteolytic attack 
As the vesicles are intended to shield SOD from proteolytic attack, we analyzed the 
FCS data of a solution of encapsulated SOD-Alexa Fluor 488 to which Proteinase K 
was added in order to see whether the latter can attack the encapsulated enzyme. 
Proteinase K is commonly used in molecular biology to digest proteins as it is highly 
active even in the presence of chemicals that denature proteins, such as SDS, urea 
or EDTA. 
The diffusion time of the vesicles that contain labeled SOD did not change when 
Proteinase K was present, proving that our vesicles protect SOD against enzymatic 
attack. 
In order to investigate whether the encapsulation procedure denatures the protein, 
we checked for possible geometry changes of the CuII metal site of the protein by 
electron paramagnetic resonance (EPR), and characterized the protein's backbone 
structure by circular dichroism (CD). 
3.3.1 Application of electron paramagnetic resonance for determination of the 
Cu site of SOD structure determination 
To characterize structural information of paramagnetic materials such as some 
transition metals and free radicals, the EPR-spectroscopy is the preferred method. 
While for crystals the x-ray crystallography is the best method for structure 
determination, the EPR-spectroscopy can provide structure informations about 
paramagnetic molecules without any limitation concerning their physical state (single 
crystals, solutions, powders, frozen solution, gases), where the resolution of x-ray 
diffraction is limited to a few Å. And the position of protons is not clearly resolved 
which further decreases the resolution of the x-ray technique. In this respect, EPR-
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spectroscopy has also a wide application in detection of biological processes, 
because the samples were measurable under physiological-like conditions. In order 
to simulate an EPR spectrum we have to take into account the interactions that are 
relevant for the paramagnetic species: (1) Gyromagnetic tensor which represents the 
interaction of the unpaired electron characterising the paramagnetic molecule and 
the external magnetic field. (2) Hyperfine interaction tensor which represents the 
interaction between the magnetic momentum of the unpaired electron and the 
magnetic momentum associated with the nuclei which form the first coordination 
sphere around the metal (in our case, copper). 
By introducing as input relevant values for the gyromagnetic and hyperfine tensors, 
according to the overall shape of the spectrum we obtain by using a simulation 
program (such as Simfonia, Bruker), a simulated spectrum as a first order simulation. 
With these values, a finer simulation is possible with optimising the parameters, until 
the best fit is obtained. This represents an iterative procedure that can be achieved 
using Minuit Simplex procedure. As soon as a reasonable simulation was obtained, 
the extracted values, especially the g-factor and the principal hyperfine constants, 
were used for structure model. Structure determination is based on comparison of 
known values for certain geometries of the first order coordination sphere around the 
metal to the ones obtained from the spectrum simulation, to predict possible 
structures of the unknown structures. 
3.3.1.1 Theory 
EPR is a technique which records a resonant absorption of a microwave radiation by 
a paramagnetic ion located in a static magnetic field. To understand this 
phenomenon, knowledge about paramagnetism, the energy-levels in a system with 
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permanent magnetic field and the principle, how to detect these transitions among 
the energy-levels is required. 
3.3.1.2 Paramagnetism 
Paramagnetism is observed in atoms, molecules and lattice-defects with an odd 
number of electrons or for free atoms and ions with partially filled inner shells. The 
magnetic moments of these atoms are weak and they have a low interaction among 
each other. They are randomly ordered, if no magnetic field is applied. When they 
are placed in a magnetic field, they will align parallel to the magnetic field, and an 
overall magnetization of the sample can be put into evidence. The alignment 
depends on the strength of the magnetic field. 
3.3.1.3 Zeeman-effect 
An electron has an intrinsic kinetic momentum which is called electron spin sr ,and 
this one can be associated with a magnetic field produced by its angular motion. So 
an electron has an magnetic moment μr . The explanation of the Zeeman-effect can 
be simply understand using a two-level system. The interaction between a magnetic 
field B0 and an unpaired electron with a magnetic moment μr  is known as the 
Zeeman-effect. Two energy-levels are possible: A lower energy level is reached, 
when the magnetic moment μr  is aligned with the magnetic field (s = -
2
1 ) and an 
upper energy-level is obtained for a magnetic moment which is aligned against the 
magnetic field (s = +
2
1 ). The energy corresponding to each orientation of the spin is 
the product of μ  and B0, where the magnetic moment μ  is defined as, 
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sg Be ⋅⋅−= μμ  Equation 8 
 
Figure 20 Energy diagramm of possible states (spin up or down). 
where the definition of the Bohr magneton B
em
he μ=⋅
⋅
2
 is. Because the spin s  can be 
up or down, the possible energy levels are: 
02
1 BgE Be ⋅⋅⋅±= μ  Equation 9 
 
The total energy-difference between the two levels is: 
BU
rr ⋅= μ  Equation 10 
 
g is the electronic splitting factor (g-factor for free electrons: ge = 2:0023192778). The 
energy levels are shown in Figure 20. An absorption in a magnetic field takes place 
when the energy of the frequency υ⋅h  is the same as the energy-difference U  of the 
two states, and this represents the resonance condition. The EPR spectra are 
obtained as first derivative of a normal absorption spectrum, for better resolution. The 
spectrum is obtained experimentally by variation of the external magnetic field, once 
the sample is placed in this field, simultaneously with the microwave irradiation of the 
sample. When the magnetic field induce a difference of the energy levels that is 
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equal to the microwave energy of irradiation, the resonance takes place and 
absorption can be seen. The signal is the first derivative ⎟⎟⎠
⎞
⎜⎜⎝
⎛
fieldmagnetic
amplitude
δ
δ . 
If we look at an electron which belongs to a molecule, its own magnetic moment will 
be changed due the interaction with the nuclei which has a magnetic momentum 
different to zero, such as N, P, Cl, etc. This represents the hyperfine interaction, and 
can be used to characterise the first order coordination sphere around the metal, or 
the structure of the free radical where the unpaired electron is delocalised. 
The formula to obtain the effective gyromagnetic value of an isotropic spectrum is 
given in Equation 11. The resulting energy υ⋅h is equal to the energy difference in 
Equation 10: 
0
4775.714
B
g υ⋅=  Equation 11 
where υ  is in Ghz and B0 is in Gaussian units. 
3.3.1.4 Principal shapes of spectra 
 The EPR can distinguish between different symmetries of the matrix in which the 
molecules can be arranged, in a referential that can be connected to the molecular 
frame. In this way the EPR spectrum analysis can give informations about the local 
symmetry in a single crystal and provide structural informations, exactly as X-ray 
diffraction. Therefore, a principal axis system exists for each paramagnetic molecule 
with the principal g-factors, gx; gy; gz, for each axis. In this way the molecular frame is 
characterised by the anisotropy of the gyromagnetic tensor. The shape of a spectrum 
directly corresponds to the absorptions along each principal axis. Different principal 
g-factors are shown in Figure 21. 
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Figure 21 The principle g-factors determine the shape of a spectrum. a) isotropic, b) 
axial, c) axial, d) rhombic. 
3.3.1.5 Hyperfine splitting 
A more complicated splitting is reached as a result of hyperfine interactions. The 
principle is the fact, that a bar magnets can be influenced by another bar magnet. 
The distance of the two bar magnet determines the strength of interaction. Therefore, 
the nuclear spin I  is involved and Equation 10 becomes IsA ⋅⋅ . A  is the principal 
hyperfine constant. The nuclear spin of copper is 
2
3
 for example. This leads to four 
absorptions, because the electronic states were split in four nuclear sub-levels 
between ( ) III ...1... +−−  for all allowed magnetic quantum numbers rM . The 
hyperfine interaction can be regarded exactly as the gyromagnetic tensor, and in this 
respect its symmetry (isotropic, axial, rhombic) can give more details for the 
geometry of the coordination sphere around the metal, and the nature of the first 
order ligand nuclei. 
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3.3.2 Integrity of the metal site of incorporated SOD 
In CuZn-SOD, CuII is located at the enzyme active site, where it plays a role in the 
disproportionation of O2•– to dioxygen and hydrogen peroxide at near diffusion-
controlled rates.[131] 
It is possible to characterize the first coordination sphere around the metal ion by 
EPR, both from the point of view of geometry and identification of nuclei with non-
zero spin, as the values of the spin Hamiltonian parameters can be related to the 
various distortions of the copper environment. 
Electron paramagnetic resonance (EPR) spectra of the solutions of incorporated 
SOD in nanocontainers were recorded at 77 K with a CW Bruker ElexSys500 X-band 
CW spectrometer, equipped with a helium temperature control system (ER4112HV), 
to which the wave-guide resonance cavity was attached. Microwave power was 
adjusted at levels below the saturation condition (2 mW for high field measurements 
and 10 mW for low field measurements). The modulation frequency was 100 kHz and 
the modulation amplitude was 0.5 mT; other spectral parameters were adjusted for 
each spectrum individually. Multiple spectra (150) were acquired to optimize the 
signal-to-noise ratio, and 3rd-order polynomial averaging was used for subsequent 
noise reduction. The spectral parameters were obtained with the SIMFONIA software 
package (Bruker Instruments Inc., Manning Park, Billerica, MA), where co-axial g and 
hyperfine tensors were assumed. Gaussian line shapes were considered with the 
line-width adjusted for each spectrum. All spectral simulations assumed natural 
abundance ratios of Cu isotopes. The g-values were referenced to 
diphenylpicryhydrazyl (DPPH) (g = 2.0036) as an external standard. 
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In Figure 22, the curve a) shows the EPR spectrum of a frozen-solution of the 
encapsulated protein, obtained after a multiple acquisition (more than 500 spectra) 
procedure. The simulation is obtained with a third-order perturbation theory approach 
(Figure 22, curve b) provides the values of the gyromagnetic and hyperfine tensors: 
g⊥ = 2.067, g⏐⏐ = 2.263; A⊥ = 4.1 mT, A⏐⏐ = 13.9 mT. These values, which are similar 
to those previously obtained for frozen solutions of bovine CuZn-SOD,[132] indicate 
that the metal site is not affected by the encapsulation procedure. The metal-binding 
site of the oxidized form of wild-type CuZn-SOD, has been characterized by X-ray 
diffraction, EPR and electronic spectroscopy and shows the CuII ion to be five-
coordinate, with four histidyl side chains in a tetrahedrally distorted arrangement and 
one axially located water molecule.[131, 133] Unfortunately, the multiple acquisition 
procedure required for the encapsulated enzyme impedes the use of either D2-EPR 
or pulse-EPR methods that would provide more information on the fine details of the 
coordination sphere of copper.[134]. 
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Figure 22 EPR spectra. a) CuZn-SOD encapsulated in nanovesicles of triblock 
copolymer PMOXA15-PDMS110-PMOXA15, at 77 K b) Simulation obtained from a 
third-order perturbation theory approach. 
3.3.3 Circular dichroism 
In order to study if the backbone of SOD was modified by encapsulation, circular 
dichroism (CD) spectra (180–260 nm) were recorded to determine the impact of the 
labeling and encapsulation conditions on the SOD molecule. Circular dichroism is a 
form of spectroscopy based on the differential absorption of left- and right handed 
circularly polarized light. Structural motifs in proteins, such as helices and sheets, are 
CD spectral signatures and can be therefore used for structural identification. 
Measurements were made with an Applied Photophysics Chirascan CD 
spectrometer. Encapsulated SOD-Alexa Fluor 488 collected from the SEC 
purification step was centrifuged with a filter device (Centricon YM-10, Millipore, 10 
kDa nominal molecular weight cutoff) at 5000 g to exchange the PBS buffer with 
MilliQ water (18 MΩ cm; Purelab UHQ, Elga) and compared with unlabeled SOD 
solubilized in MilliQ water. 
The CD spectra of SOD-Alexa Fluor 488 before and after the encapsulation 
procedure (Figure 23) differ only in signal intensity, which is due to sample 
concentrations. This indicates that if the encapsulation caused any changes to the 
protein backbone, these changes were reversible.[135] 
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Figure 23 CD Spectra. a) SOD-Alexa Fluor 488 separated from SOD-filled 
nanovesicles by SEC. b) SOD-Alexa Fluor 488 not exposed to the encapsulation 
conditions. 
3.4 Quantification of the anti-inflammatory capacity of encapsulated 
SOD 
3.4.1 Pulse radiolysis as a method to determine the SOD activity 
The activity of SOD in the polymeric nanovesicles was investigated by pulse 
radiolysis with a Febetron 705 (Titan Systems Corp., San Leandro, CA, USA) 2.3-
MeV accelerator with a pulse width (fwhm) of <50 ns as the radiation source; the 
optical system consists of a 75-W Xe arc lamp (Hamamatsu, Schüpfen, Switzerland), 
a 1- or 2-cm-optical-path quartz cell (Hellma GmbH and Co. KG, Müllheim, 
Germany), and an Acton SP300i monochromator (Roper Scientific, Ottobrunn, 
Germany). For signal detection of kinetic traces, a R928 photomultiplier 
(Hamamatsu) with a DHPCA-200 amplifier (Femto Messtechnik GmbH, Berlin, 
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Germany) with a DL7100 digital storage oscilloscope (Yokogawa Electric 
Corporation, Tokyo, Japan) is used; a Princeton Instruments PI-MAX 512T gateable 
ICCD camera (Roper Scientific) is used for detection of time-resolved spectra. O2•– is 
formed by irradiation of oxygenated sodium formate (1 M) solutions at pH 8.5. SOD 
activity is calculated from rates of decay of O2•–, measured at 280 nm, in the 
presence and absence of SOD. Doses between 10 and 50 Gy/pulse were applied. 
When experiments with vesicles are carried out, extensive light scattering is 
observed, which results in a lower signal amplitude. The 100 Hz ripple is caused by 
the electronic equipment. 
3.4.2 SOD activity assay of nanocontainers encapsulating SOD 
We performed pulse radiolysis measurements on series of free and encapsulated 
SOD samples to determine whether encapsulated SOD remains active. CuZn-SOD is 
active across a wide pH range (5.0–9.5) and under various environmental 
conditions,[124, 136, 137] thus, we hypothesized that the protein's function would not 
be affected by the encapsulation procedure. Our hypothesis was supported by 
observations that encapsulated SOD remains structurally intact. We have previously 
succeeded in encapsulating other proteins in nanovesicles, for example, β-lactamase 
and the purine-specific nucleoside hydrolase of Trypanosoma ViVax (TvNH), and 
found that activity was preserved.[23, 138] 
In pulse radiolysis, the kinetics of the superoxide anions dismutation is measured 
directly; the method is sensitive (10 nM), accurate, and reproducible. Figure 24-1 
shows the rate of dismutation of the superoxide anion in the presence of empty 
nanovesicles (curve a, t½ ≈ 300 ms) compared to SOD-filled nanovesicles (curve b, t½ 
≈ 4 ms). The very rapid dismutation of superoxide anions in the presence of 
 76 
 
encapsulated SOD, together with the finding that SOD is present only in the inner 
space of the nanovesicles, demonstrates that the nanovesicles are permeable to 
superoxide and HO2•, and may be described as nanoreactors. The in situ activity 
assays together with structural characterization of the protein establish that no 
changes to the protein occur during the encapsulation procedure. The reaction rate 
of the encapsulated enzyme is similar to that of the free enzyme (Figure 24), which 
indicates that the diffusion of O2•– through the triblock copolymer wall is not rate-
limiting. 
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Figure 24 1) Pulse radiolysis assay. 1a) Uncatalyzed decay observed at 280 nm of 
80 µM superoxide produced by a 50 ns pulse of an aerated solution of 1.0 M formate 
and 10 mM phosphate, pH 8. 1b) Superoxide decay catalyzed by SOD (ca. 0.12 µM) 
encapsulated in PMOXA15-PDMS110-PMOXA15 vesicles (10 mg polymer). 2) Pulse 
radiolysis standard curve for different concentrations of SOD. 
We constructed a calibration curve from a series of pulse-radiolysis determinations of 
the activity of free SOD in solution (Figure 24-2) and, assuming free diffusion of 
superoxide, used the curve to calculate the amount of SOD encapsulated. By taking 
into account the number of nanovesicles formed in the solution of 10 mg/ml of 
polymer with a weight average molar mass M = 3.4 × 108 g/mol (determined from LS 
experiments) and the concentration of encapsulated SOD (determined by pulse 
radiolysis), the average encapsulation number is 10 protein molecules/nanovesicle 
(for an initial concentration of SOD of 0.3 mg/ml). This value is slightly higher than 
the maximum average number of encapsulated SOD-Alexa Fluor 488 molecules 
obtained from molecular brightness measurements, where only labeled-SOD 
molecules are counted (non-labeled protein molecules are invisible). We emphasize 
that within the experimental errors and inherent limitations of each method, the 
results of these two independent methods are in good agreement. Due to the small 
number of encapsulated SOD molecules the intermolecular interactions or 
conformational changes due to confinement of SOD in the nanovesicles can be 
considered negligible. Because of the mild encapsulation that occurs during the self-
assembly process of nanovesicle formation, as well as the experimental conditions 
aimed at restricting the number of enzyme molecules encapsulated, SOD remains 
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fully active and the dismutation of superoxide takes place in the inner space of the 
nanoreactor. 
According to studies on the permeability of bilayer lipid membranes to superoxide 
radicals, the transport of O2•– is strongly dependent on the structural state of the 
membrane and on the localization of the substrate; the permeability coefficient 
estimated at 2.1 × 10–6 – 7.6 × 10–8 cm/s in lipids.[139, 140] Generally, for lipid 
bilayers, channels for anion transport must be incorporated, and the bilayers tend to 
break down and release encapsulated compounds over time. However, the polymeric 
nanoreactors described here are permeable to both dioxygen and superoxide and do 
not require anion channels.[4, 23, 141, 142] As the protein acts inside the polymer 
vesicles, our nanoreactor is inherently simpler and overcomes the problems 
connected to efficient release in the body, which are common to conventional 
carriers, such as liposomes and other polymeric nanocontainers. The antioxidant 
nanoreactor is not limited to use with superoxide dismutase, it can be chemically 
modified for specific targeting approaches and enables the simultaneous 
encapsulation of other proteins to extend its applicability. 
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4 A Total antioxidant nanoreactor 
4.1 The Concept and goal of the co-encapsulation 
As described in paragraphs 2.2 (Equation 2) and 2.3.1 (Equation 5, Equation 6), 
SOD converts superoxide anions to hydrogen peroxide and dioxygen as the part of a 
natural antioxidant defense mechanism. Hydrogen peroxide itself is weak, and 
compared to the half-life of O2•–, quite stable. Therefore it needs to be degraded to 
achieve a sufficient antioxidant effect of the antioxidant nanoreactors in vivo. In order 
to obtain a total antioxidant nanoreactor we propose to co-encapsulate SOD and 
horseradish peroxidase (HRP). These two enzymes would act together in a cascade 
reaction and fully convert O2•– via hydrogen peroxide to water and dioxygen. 
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Figure 25 A schematic drawing of the concept and mechanism of the 
coencapsulation of an enzymatic cascade detoxifying O2•–. 
Firstly, catalase was chosen as the second enzyme, in order to be co-encapsulated 
with SOD. Preliminary tests to establish the experimental methods to track catalase 
inside vesicles showed that neither hydrogen peroxide as reactant, nor water or 
dioxygen as products, offer the possibility of spectrophotometric detection at very low 
concentrations which predominate inside the nanoreactor. Therefore horseradish 
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peroxidase (HRP), as a second enzyme to enable a cascade reaction towards a 
complete detoxification of superoxide radicals. HRP is a heme-containing enzyme of 
40 kDa, which catalyses the reduction of hydrogen peroxide to water. In the presence 
of specific substrates, which act as hydrogen donors, HRP can oxidize these 
substrates by using hydrogen peroxide. We chose the fluorescent dye Amplex Red 
(AmpR) for tracking hydrogen peroxide degradation. In the presence of HRP, the 
AmpR reacts in a 1:1 stoichiometry with hydrogen peroxide to produce highly 
fluorescent resorufin (Figure 26). This way the use of AmpR allows to detect if the co-
encapsulated enzymes work sequentially to detoxify O2•– in water and dioxygen. 
 
Figure 26 Reaction of AmpR to resorufin, catalyzed by the enzyme HRP 
4.2 Preliminary results on SOD-HRP co-encapsulation 
The co-encapsulation was accomplished like the encapsulation of SOD described in 
paragraph 3.2.2. The following concentrations of the enzymes and fluorescent dye 
were used: SOD (0.5 mg/ml), HRP (0.2 mg/ml) and AmpR (0.012 mg/ml). The 
nanocontainers with co-encapsulated SOD, HRP and AmpR were purified as 
described above (paragraph 3.2.2). 
A xanthine/ xanthine oxidase reaction was used to generate superoxide anions. 
Xanthine oxidase is found in mammal liver and is responsible for the catalysis of 
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hypoxanthine to xanthine oxidation (Equation 12), and can further catalyze the 
oxidation of xanthine to uric acid and superoxide (Equation 13). 
hypoxanthine  +  O2  +  H2O  →  xanthine  +  H2O2 Equation 12 
 
xanthine  +  O2  +  H2O  →  uric acid  +  O2•– Equation 13 
Several control experiments were accomplished: 
a. The reliability of the superoxide anion production was proved by measuring the 
kinetics of the reaction, following the appearance of uric acid at 290 nm (Figure 27). 
The concept of the cascade reaction of SOD, HRP and AmpR was proved by adding 
them together in a reaction vessel without encapsulation (Figure 28-a). The 
concentrations of the reactants were similar to those in the encapsulation 
experiment, described above. 
To prove if xanthine oxidase or the product of its reaction with xanthine can oxidize 
AmpR, they were mixed together. Figure 28-b shows clearly, that xanthine oxidase or 
its product does not react with AmpR. 
The purified nanocontainers, xanthine (0.15 mM, pH 7.5) and xanthine oxidase (0.5 
u/mL, 50 mM potassium phosphate buffer, pH 7.5) were mixed in a ratio of 1:1:1 
(v:v:v). The kinetics of the reaction was measured by fluorescence spectroscopy 
using a luminescence spectrometer LS55 (Perkin Elmer) and analysis software FL 
Winlab (Perkin Elmer). The mixture was excited at 530 nm and the emission of the 
sample was measured at 580 nm. Figure 28 shows that the cascade reaction of 
SOD, HRP and AmpR worked properly. 
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Figure 27 Kinetics of the appearance of uric acid, produced by xanthine/ xanthine 
oxidase. 
 
Figure 28 a) Kinetics of the reaction of SOD, HRP and AmpR (not encapsulated). 
Superoxide was generated using xanthine/ xanthine oxidase. b) Kinetics of the 
reaction of AmpR with xanthine/ xanthine oxidase. Both measurements were 
accomplished at λex: 530 nm, λem: 580 nm. 
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Preliminary tests showed, that O2•–, generated by xanthine/ xanthine oxidase is able 
to cause a reaction in the presence of nanocontainers, although the received change 
in the fluorescence signal is close to the detection limit of the used luminescence 
spectrometer (Figure 29). Figure 29 shows that after an initial decrease of the 
fluorescence signal a clear increase appears which is related to the conversion of 
AmpR to resurofin by HRP. A reason for this low yield in fluorescence intensity can 
be the autooxidation of amplex red and its low amount encapsulated in the 
nanocontainers. Further experiments are planned to improve the conditions to 
establish and characterize the cascade reaction in situ in vesicles and test the 
efficiency of the complete antioxidant nanoreactors. 
 
Figure 29 Kinetics of the conversion of AmpR to Resurofin encapsulated in 
nanocontainer with coencapsulated SOD, HRP, AmpR after addition of xanthine/ 
xanthine oxidase. Measurement was accomplished at λex: 530 nm, λem: 580 nm. 
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5 Materials for encapsulation of SOD, HRP, AmpR in 
nanocontainers 
5.1 Shielding of SOD by encapsulation in polymeric nanocontainer 
CuZn-SOD from bovine erythrocytes (Sigma Aldrich), Alexa Fluor® 488 (Invitrogen), 
dimethylsulfoxide (DMSO; Aldrich), Sephadex G-50 (Fluka), uranyl acetate (Sigma 
Aldrich), and ethanol (99.8 %; Fluka) were used without any further treatment. 
Sepharose 4B (Sigma Aldrich) and polycarbonate membrane filters (Millipore, 
200 nm) were used. Alexa Fluor 488 (Invitrogen) was used as described in the 
manufacturer's protocol (MP00143, http://www.invitrogen.com). Proteinase K (Roche) 
was used as described in the manufacturer’s protocol. 
5.2 Co-encapsulation of SOD, HRP, AmpR 
CuZn-SOD from bovine erythrocytes (Sigma Aldrich), HRP from horseradish (Sigma), 
dimethylsulfoxide (DMSO; Aldrich), potassium phosphate (Sigma), Sephadex G-50 
(Fluka), and ethanol (99.8 %; Fluka) were used without any further treatment. 
Sepharose 4B (Sigma Aldrich) and polycarbonate membrane filters (Millipore, 200 
nm) were used. Amplex Red (Invitrogen) was used as described in the 
manufacturer's protocol (http://www.invitrogen.com). Xanthine/ xanthine oxidase 
(Sigma) was used as described in the manufacturers protocol (X1875). 
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6 Conclusions 
We designed and tested novel antioxidant nanoreactors based on encapsulation of 
SOD in superoxide radical-permeable nanovesicles. This represents the first 
example of an antioxidant nanoreactor which overcomes the problems linked to 
conventional drug delivery systems. SOD encapsulated in block copolymer 
nanovesicles formed via self-assembly, is located in the inner cavity of the 
nanovesicles, and the mild encapsulation process does not affect the structural or 
functional integrity of the enzyme. The polymeric membrane of the nanovesicles is 
capable of both protecting the encapsulated SOD and allowing penetration by O2•–, 
where the conversion to hydrogen peroxide and oxygen is catalyzed. Compared with 
conventional drug nanocarriers made of liposomes or polymers, our system 
combines the advantages of a polymer shield with an in situ active protein. The tight 
polymeric membrane of the nanovesicles prevents release of the encapsulated 
protein from the nanoreactor.[119] The sensitivity of this nanoreactor is high, as 
proved by the observation that SOD activity was measured although the number of 
encapsulated SOD molecules is small. The production of nanoreactors is 
straightforward, involving simple self-assembly of the amphiphilic copolymer in the 
presence of the protein. The level of superoxide permeability obviates the necessity 
of inserting artificial channels in the polymer membrane, as usually done with 
nanoreactors.[4, 23, 141, 142] The antioxidant nanoreactors remain stable over 
several weeks of storage at 4 °C. Selective permeability of the polymeric membrane 
may be generally useful to improve the bioavailability of proteinaceous 
pharmaceuticals. The association of the second enzyme inside the nanoreactor, 
 87 
 
which can convert hydrogen peroxide to water, represents a step further to obtain a 
complete antioxidant nanoreactor. Preliminary tests were performed to study the 
conditions specific for the cascade reaction involving SOD and HRP together. Further 
experiments are planned to improve the system of the cascade reaction in situ in 
vesicles and test the efficiency of the complete antioxidant nanoreactor. 
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